<< Back to News

IBRANCE® (palbociclib) Indications Now Include Male Patients

Pfizer Oncology is proud to announce that the indications for IBRANCE® (palbociclib) now include male patients as shown below:

IBRANCE is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with:

  • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or
  • fulvestrant in patients with disease progression following endocrine therapy

Based on limited data from post-marketing reports and electronic health records, the safety profile for men treated with IBRANCE is consistent with the safety profile in women treated with IBRANCE. The recommended dosing regimen is also consistent for male and female patients.

For patients requiring financial assistance, Pfizer Oncology has support programs that may be able to help. You can learn more at the product website IBRANCEhcp.com.

Full updated prescribing information is available here.